Literature DB >> 22109320

CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab.

Piyaporn Boonsirikamchai1, Mohamed Aly Asran, Dipen M Maru, Jean-Nicolas Vauthey, Harmeet Kaur, Scott Kopetz, Evelyne M Loyer.   

Abstract

OBJECTIVE: The purpose of this article is to provide a practical review of newly established morphologic tumor response criteria for hepatic colorectal metastasis treated with bevacizumab-containing chemotherapy and a description of the patterns of early recurrence. We also discuss the respective value of these criteria and the Response Evaluation Criteria in Solid Tumors (RECIST).
CONCLUSION: RECIST alone are not sufficient to assess response after bevacizumab-containing chemotherapy for hepatic colorectal metastasis. The combined use of RECIST and morphologic criteria is mandatory for optimal evaluation in this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109320     DOI: 10.2214/AJR.11.6459

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

1.  Stem cell gene Girdin: a potential early liver metastasis predictor of colorectal cancer.

Authors:  Chen Liu; Hongpeng Xue; Yixia Lu; Baorong Chi
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

2.  Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

Authors:  R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

Review 3.  Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.

Authors:  Sean M Ronnekleiv-Kelly; Richard A Burkhart; Timothy M Pawlik
Journal:  Surg Oncol       Date:  2016-05-20       Impact factor: 3.279

4.  SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer.

Authors:  R García-Carbonero; R Vera; F Rivera; E Parlorio; M Pagés; E González-Flores; C Fernández-Martos; M Á Corral; R Bouzas; F Matute
Journal:  Clin Transl Oncol       Date:  2016-05-20       Impact factor: 3.405

5.  Evaluation of cancer treatment in the abdomen: Trends and advances.

Authors:  Silanath Peungjesada; Hubert H Chuang; Srinivasa R Prasad; Haesun Choi; Evelyne M Loyer; Yulia Bronstein
Journal:  World J Radiol       Date:  2013-03-28

Review 6.  [Computed tomography and/or magnetic resonance imaging of the liver : How, why, what for?]

Authors:  G H Pöhler; K I Ringe
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

Review 7.  Functional imaging biomarkers for assessing response to treatment in liver and lung metastases.

Authors:  Livia Bernardin; Elizabeth A M O'Flynn; Nandita M Desouza
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

8.  Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.

Authors:  Sophia Frentzas; Eve Simoneau; Victoria L Bridgeman; Peter B Vermeulen; Shane Foo; Eleftherios Kostaras; Mark Nathan; Andrew Wotherspoon; Zu-Hua Gao; Yu Shi; Gert Van den Eynden; Frances Daley; Clare Peckitt; Xianming Tan; Ayat Salman; Anthoula Lazaris; Patrycja Gazinska; Tracy J Berg; Zak Eltahir; Laila Ritsma; Jacco Van Rheenen; Alla Khashper; Gina Brown; Hanna Nystrom; Malin Sund; Steven Van Laere; Evelyne Loyer; Luc Dirix; David Cunningham; Peter Metrakos; Andrew R Reynolds
Journal:  Nat Med       Date:  2016-10-17       Impact factor: 53.440

9.  Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Authors:  Riccardo Ricotta; Antonella Verrioli; Silvia Ghezzi; Luca Porcu; A Grothey; Alfredo Falcone; Eric Van Cutsem; Guillem Argilés; Antoine Adenis; Marc Ychou; Carlo Barone; Olivier Bouché; Marc Peeters; Yves Humblet; Laurent Mineur; Alberto F Sobrero; Joleen M Hubbard; Chiara Cremolini; Hans Prenen; Josep Tabernero; Hajer Jarraya; Thibault Mazard; Sophie Deguelte-Lardiere; Konstantinos Papadimitriou; Marc Van den Eynde; Alessandro Pastorino; Daniela Redaelli; Katia Bencardino; Chiara Funaioli; Alessio Amatu; Giulia Carlo-Stella; Valter Torri; Andrea Sartore-Bianchi; Angelo Vanzulli; Salvatore Siena
Journal:  ESMO Open       Date:  2017-02-13

10.  Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases.

Authors:  Kyriakos Neofytou; Alexandros Giakoustidis; Mafalda Costa Neves; Dawn Morrison; Dimitris Giakoustidis; Aamir Z Khan; Justin Stebbing; Satvinder Mudan
Journal:  Langenbecks Arch Surg       Date:  2016-04-04       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.